Zymeworks Inc. (ZYME) Stock Grade

About Zymeworks Inc.'s fundamentals

Zymeworks is a biotechnology company with a market capitalization of $2.0 billion that has demonstrated strong revenue growth of 38.9% year-over-year, indicating expanding commercial traction or increased research activity. However, the company operates at a significant net loss with a negative net margin of -76.6%, meaning it is currently spending substantially more than it generates in revenue, which is not uncommon for development-stage biotech firms investing heavily in research and drug development. The company does not pay a dividend, which is typical for companies prioritizing reinvestment in their pipeline and operations rather than returning capital to shareholders.